Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
4.
Best Pract Res Clin Anaesthesiol ; 36(1): 179-189, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-35659954

RESUMEN

Epidural analgesia, commonly used to alleviate labor pain, is not without complication. The most common complication associated with labor epidural analgesia (LEA) is Unintentional Dural Puncture (UDP), where many professionals go on to develop a Post Dural Puncture Headache (PDPH). Spinal anesthesia can also result in PDPH. Other complications of dural puncture necessitating further treatment include hospital readmission, persistent headache, persistent backache, cerebral venous thrombosis, subdural hematoma, postpartum depression, post-traumatic stress disorder, and decreased maternal breastfeeding. In this article, we will define and discuss the definition and diagnosis for PDPH, the pathophysiology of PDPH, PDPH treatment options including conservative therapy, pharmacologic therapy, and invasive procedural measures including the therapeutic epidural blood patch, prophylactic epidural blood patch, intrathecal catheter placement after UDP, and potential new therapies.


Asunto(s)
Anestesia Obstétrica , Anestesia Raquidea , Cefalea Pospunción de la Duramadre , Anestesia Obstétrica/efectos adversos , Anestesia Raquidea/efectos adversos , Parche de Sangre Epidural/efectos adversos , Femenino , Humanos , Cefalea Pospunción de la Duramadre/diagnóstico , Cefalea Pospunción de la Duramadre/etiología , Cefalea Pospunción de la Duramadre/terapia , Embarazo , Uridina Difosfato
5.
Am J Reprod Immunol ; 88(2): e13559, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35514201

RESUMEN

PROBLEM: We evaluated eculizumab, a complement protein C5 inhibitor, for treatment of severe COVID-19 in pregnant and postpartum individuals. METHOD OF STUDY: Protocol ECU-COV-401 (clinicaltrials.gov NCT04355494) is an open label, multicenter, Expanded Access Program (EAP), evaluating eculizumab for treatment of severe COVID-19. Participants enrolled at our center from August 2020 to February 2021. Hospitalized patients were eligible if they had severe COVID-19 with bilateral pulmonary infiltrates and oxygen requirement. Eculizumab was administered on day 1 (1200 mg IV) with additional doses if still hospitalized (1200 mg IV on Days 4 and 8; 900 mg IV on Days 15 and 22; optional doses on Days 12 and 18). The primary outcome was survival at Day 15. Secondary outcomes included survival at Day 29, need for mechanical ventilation, and duration of hospital stay. We evaluated pharmacokinetic and pharmacodynamic data, safety, and adverse outcomes. RESULTS: Eight participants were enrolled at the Cedars-Sinai Medical Center, six during pregnancy (mean 30 ± 4.0 weeks) and two in the postpartum period. Baseline oxygen requirement ranged from 2 L/min nasal cannula to 12 L/min by non-rebreather mask. The median number of doses of eculizumab was 2 (range 1-3); the median time to hospital discharge was 5.5 days (range 3-12). All participants met the primary outcome of survival at Day 15, and all were alive and free of mechanical ventilation at Day 29. In three participants we demonstrated that free C5 and soluble C5b-9 levels decreased following treatment. There were no serious adverse maternal or neonatal events attributed to eculizumab at 3 months. CONCLUSION: We describe use of eculizumab to treat severe COVID-19 in a small series of pregnant and postpartum adults. A larger, controlled study in pregnancy is indicated.


Asunto(s)
Anticuerpos Monoclonales Humanizados , Tratamiento Farmacológico de COVID-19 , Adulto , Anticuerpos Monoclonales Humanizados/uso terapéutico , Proteínas del Sistema Complemento , Femenino , Humanos , Recién Nacido , Oxígeno , Embarazo , SARS-CoV-2 , Resultado del Tratamiento
6.
Biomed Res Int ; 2019: 4618798, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31531352

RESUMEN

This Pro-Con debate will provide the practitioner with an evidence-based knowledge approach to assist the clinician in determining whether to employ (Pro) or not to employ (Con) this technique in the obstetrical suite for labor analgesia. Nitrous oxide has been used safely in dentistry and medicine for many centuries. However, accumulating preclinical and clinical evidence increasingly suggests previously unrecognized adverse maternal and fetal effects of nitrous oxide, which warrants reconsideration of its use in pregnant women and a more detailed informed consent. Nitrous oxide is associated with metabolic, oxidative, genotoxic, and transgenerational epigenetic effects in animals and humans that may warrant limiting its usefulness in labor. This debate will discuss and review the clinical uses, advantages, and disadvantages of nitrous oxide on occupational effects of nitrous oxide exposure, neuroapoptosis, FDA warning on inhalational anesthetics and the developing brain, research limitations, occupational exposure safety limits, effects on global warming, and potential for diversion.


Asunto(s)
Anestésicos por Inhalación/efectos adversos , Óxido Nitroso/efectos adversos , Anestésicos por Inhalación/farmacología , Anestésicos por Inhalación/uso terapéutico , Animales , Femenino , Feto/efectos de los fármacos , Humanos , Trabajo de Parto/efectos de los fármacos , Óxido Nitroso/farmacología , Óxido Nitroso/uso terapéutico , Manejo del Dolor/efectos adversos , Manejo del Dolor/métodos , Embarazo
9.
AJP Rep ; 7(2): e93-e100, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28497007

RESUMEN

Objective This study aims to compare the accuracy of visual, quantitative gravimetric, and colorimetric methods used to determine blood loss during cesarean delivery procedures employing a hemoglobin extraction assay as the reference standard. Study Design In 50 patients having cesarean deliveries blood loss determined by assays of hemoglobin content on surgical sponges and in suction canisters was compared with obstetricians' visual estimates, a quantitative gravimetric method, and the blood loss determined by a novel colorimetric system. Agreement between the reference assay and other measures was evaluated by the Bland-Altman method. Results Compared with the blood loss measured by the reference assay (470 ± 296 mL), the colorimetric system (572 ± 334 mL) was more accurate than either visual estimation (928 ± 261 mL) or gravimetric measurement (822 ± 489 mL). The correlation between the assay method and the colorimetric system was more predictive (standardized coefficient = 0.951, adjusted R2 = 0.902) than either visual estimation (standardized coefficient = 0.700, adjusted R2 = 00.479) or the gravimetric determination (standardized coefficient = 0.564, adjusted R2 = 0.304). Conclusion During cesarean delivery, measuring blood loss using colorimetric image analysis is superior to visual estimation and a gravimetric method. Implementation of colorimetric analysis may enhance the ability of management protocols to improve clinical outcomes.

10.
J Clin Anesth ; 35: 136-144, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27871511

RESUMEN

STUDY OBJECTIVES: To review the clinical and basic science literature regarding Zika viral illness and highlight relevant findings for obstetric anesthesiologists. This review provides a global review of Zika viral illness, transmission patterns, pathophysiology of disease, and anesthetic management of the parturient with Zika viral illness and associated comorbidities. DESIGN: Systematic review. SETTING: Large academic hospital. SUBJECTS: None. INTERVENTIONS: None. MEASUREMENTS: None. MAIN RESULTS: None. CONCLUSION: With the rapid spread of Zika virus and expected increase of spread in the summer of 2016, this review provides anesthesiologists with current recommendations, physiologic alterations, and anesthetic considerations in regard to the parturient with Zika viral illness and associated diseases.


Asunto(s)
Anestesia Obstétrica/métodos , Patógenos Transmitidos por la Sangre , Síndrome de Guillain-Barré/complicaciones , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Infección por el Virus Zika/complicaciones , Infección por el Virus Zika/transmisión , Virus Zika/patogenicidad , Aedes/virología , Animales , Femenino , Síndrome de Guillain-Barré/epidemiología , Síndrome de Guillain-Barré/virología , Humanos , Incidencia , Embarazo , Estados Unidos/epidemiología , Infección por el Virus Zika/epidemiología , Infección por el Virus Zika/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA